Can Mixed Financials Have A Negative Impact on Haleon plc's 's (LON:HLN) Current Price Momentum?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2024
0mins
Source: Yahoo Finance
Haleon's Financial Performance: Haleon's stock has increased by 3.9% recently, but its Return on Equity (ROE) of 7.5% is significantly lower than the industry average of 32%, contributing to a low net income growth of 2.7% over the past five years.
Future Outlook: Despite current challenges, analysts predict an increase in Haleon's ROE to 9.5% and accelerated earnings growth due to a planned reduction in the payout ratio from 47% to 37% over the next three years.
Analyst Views on HLN
Wall Street analysts forecast HLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HLN is 13.44 USD with a low forecast of 13.44 USD and a high forecast of 13.44 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 10.330
Low
13.44
Averages
13.44
High
13.44
Current: 10.330
Low
13.44
Averages
13.44
High
13.44
About HLN
Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
